BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1546 related articles for article (PubMed ID: 25927346)

  • 1. PRMT5- mediated symmetric arginine dimethylation is attenuated by mutant huntingtin and is impaired in Huntington's disease (HD).
    Ratovitski T; Arbez N; Stewart JC; Chighladze E; Ross CA
    Cell Cycle; 2015; 14(11):1716-29. PubMed ID: 25927346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Huntingtin-mediated axonal transport requires arginine methylation by PRMT6.
    Migazzi A; Scaramuzzino C; Anderson EN; Tripathy D; Hernández IH; Grant RA; Roccuzzo M; Tosatto L; Virlogeux A; Zuccato C; Caricasole A; Ratovitski T; Ross CA; Pandey UB; Lucas JJ; Saudou F; Pennuto M; Basso M
    Cell Rep; 2021 Apr; 35(2):108980. PubMed ID: 33852844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease.
    Hermel E; Gafni J; Propp SS; Leavitt BR; Wellington CL; Young JE; Hackam AS; Logvinova AV; Peel AL; Chen SF; Hook V; Singaraja R; Krajewski S; Goldsmith PC; Ellerby HM; Hayden MR; Bredesen DE; Ellerby LM
    Cell Death Differ; 2004 Apr; 11(4):424-38. PubMed ID: 14713958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A series of N-terminal epitope tagged Hdh knock-in alleles expressing normal and mutant huntingtin: their application to understanding the effect of increasing the length of normal Huntingtin's polyglutamine stretch on CAG140 mouse model pathogenesis.
    Zheng S; Ghitani N; Blackburn JS; Liu JP; Zeitlin SO
    Mol Brain; 2012 Aug; 5():28. PubMed ID: 22892315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of Twist1 in mutant huntingtin-induced transcriptional alterations and neurotoxicity.
    Pan Y; Zhu Y; Yang W; Tycksen E; Liu S; Palucki J; Zhu L; Sasaki Y; Sharma MK; Kim AH; Zhang B; Yano H
    J Biol Chem; 2018 Jul; 293(30):11850-11866. PubMed ID: 29891550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease.
    Wellington CL; Ellerby LM; Gutekunst CA; Rogers D; Warby S; Graham RK; Loubser O; van Raamsdonk J; Singaraja R; Yang YZ; Gafni J; Bredesen D; Hersch SM; Leavitt BR; Roy S; Nicholson DW; Hayden MR
    J Neurosci; 2002 Sep; 22(18):7862-72. PubMed ID: 12223539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The regulation of autophagosome dynamics by huntingtin and HAP1 is disrupted by expression of mutant huntingtin, leading to defective cargo degradation.
    Wong YC; Holzbaur EL
    J Neurosci; 2014 Jan; 34(4):1293-305. PubMed ID: 24453320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcriptional dysregulation of coding and non-coding genes in cellular models of Huntington's disease.
    Bithell A; Johnson R; Buckley NJ
    Biochem Soc Trans; 2009 Dec; 37(Pt 6):1270-5. PubMed ID: 19909260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain.
    Ginés S; Bosch M; Marco S; Gavaldà N; Díaz-Hernández M; Lucas JJ; Canals JM; Alberch J
    Eur J Neurosci; 2006 Feb; 23(3):649-58. PubMed ID: 16487146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of huntingtin with PRMTs and its subsequent arginine methylation affects HTT solubility, phase transition behavior and neuronal toxicity.
    Ratovitski T; Jiang M; O'Meally RN; Rauniyar P; Chighladze E; Faragó A; Kamath SV; Jin J; Shevelkin AV; Cole RN; Ross CA
    Hum Mol Genet; 2022 May; 31(10):1651-1672. PubMed ID: 34888656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice.
    Boudreau RL; McBride JL; Martins I; Shen S; Xing Y; Carter BJ; Davidson BL
    Mol Ther; 2009 Jun; 17(6):1053-63. PubMed ID: 19240687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutant huntingtin promotes the fibrillogenesis of wild-type huntingtin: a potential mechanism for loss of huntingtin function in Huntington's disease.
    Busch A; Engemann S; Lurz R; Okazawa H; Lehrach H; Wanker EE
    J Biol Chem; 2003 Oct; 278(42):41452-61. PubMed ID: 12888569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis.
    Kim YJ; Yi Y; Sapp E; Wang Y; Cuiffo B; Kegel KB; Qin ZH; Aronin N; DiFiglia M
    Proc Natl Acad Sci U S A; 2001 Oct; 98(22):12784-9. PubMed ID: 11675509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage.
    Shirendeb U; Reddy AP; Manczak M; Calkins MJ; Mao P; Tagle DA; Reddy PH
    Hum Mol Genet; 2011 Apr; 20(7):1438-55. PubMed ID: 21257639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets.
    Jiang M; Wang J; Fu J; Du L; Jeong H; West T; Xiang L; Peng Q; Hou Z; Cai H; Seredenina T; Arbez N; Zhu S; Sommers K; Qian J; Zhang J; Mori S; Yang XW; Tamashiro KL; Aja S; Moran TH; Luthi-Carter R; Martin B; Maudsley S; Mattson MP; Cichewicz RH; Ross CA; Holtzman DM; Krainc D; Duan W
    Nat Med; 2011 Dec; 18(1):153-8. PubMed ID: 22179319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice.
    Apostol BL; Simmons DA; Zuccato C; Illes K; Pallos J; Casale M; Conforti P; Ramos C; Roarke M; Kathuria S; Cattaneo E; Marsh JL; Thompson LM
    Mol Cell Neurosci; 2008 Sep; 39(1):8-20. PubMed ID: 18602275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking.
    Orr AL; Li S; Wang CE; Li H; Wang J; Rong J; Xu X; Mastroberardino PG; Greenamyre JT; Li XJ
    J Neurosci; 2008 Mar; 28(11):2783-92. PubMed ID: 18337408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PPAR-δ is repressed in Huntington's disease, is required for normal neuronal function and can be targeted therapeutically.
    Dickey AS; Pineda VV; Tsunemi T; Liu PP; Miranda HC; Gilmore-Hall SK; Lomas N; Sampat KR; Buttgereit A; Torres MJ; Flores AL; Arreola M; Arbez N; Akimov SS; Gaasterland T; Lazarowski ER; Ross CA; Yeo GW; Sopher BL; Magnuson GK; Pinkerton AB; Masliah E; La Spada AR
    Nat Med; 2016 Jan; 22(1):37-45. PubMed ID: 26642438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysregulation of REST-regulated coding and non-coding RNAs in a cellular model of Huntington's disease.
    Soldati C; Bithell A; Johnston C; Wong KY; Stanton LW; Buckley NJ
    J Neurochem; 2013 Feb; 124(3):418-30. PubMed ID: 23145961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arginine methylation of RNA-binding proteins is impaired in Huntington's disease.
    Ratovitski T; Kamath SV; O'Meally RN; Gosala K; Holland CD; Jiang M; Cole RN; Ross CA
    Hum Mol Genet; 2023 Oct; 32(20):3006-3025. PubMed ID: 37535888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 78.